CHF Solutions Retains CORE IR as its Investor Relations Firm of Record


EDEN PRAIRIE, Minn., May 24, 2017 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS) announced today that it has retained CORE IR as its Investor Relations firm of record. Core IR will provide investor relations and shareholder communications services and assist the company in expanding market awareness and engagement with the institutional and retail investment communities.

CORE IR represents itself as a boutique investor relations firm that specializes in leveraging investment, growth, and exposure strategies for small to mid-sized companies through an integrated approach to relationship development and shareholder communications.

"We are pleased to engage CORE IR, whose experience and expertise will help to broaden CHF Solutions’ visibility and engagement with the market,” said John Erb, Chief Executive Officer and President of CHF Solutions. “We are keenly focused on strengthening our relationships within the institutional and retail segments, to convey the value thesis that CHF Solutions represents. With Core IR, we will enhance our shareholder communications and investor outreach and look forward to working with the CORE IR team in expanding our IR efforts,” Mr. Erb concluded.

“The CORE IR team is thrilled to support CHF Solutions in expanding their Investor Relations efforts with targeted investor outreach and enhanced shareholder communications,” said Scott Gordon, President of CORE IR. “The company’s fundamentals are evolving with promise and together we will carry forward their investment theses to the market in support of their Investor Relations objectives,” he added.

About CHF Solutions
CHF Solutions, Inc. (NASDAQ:CHFS) is an early-stage medical device company focused on commercializing the Aquadex FlexFlow® System. The company's commercial product, the Aquadex system, is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. Its objective is to improve the quality of life for patients with heart failure and related conditions. CHF Solutions is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland. The Company has been listed on the NASDAQ Capital Market since February 2012.

Forward-Looking Statements
Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements that address the expected results of the company retaining CORE IR, future operating performance, the promise of evolving fundamental, and events or developments that we expect or anticipate will occur in the future. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our recently announced strategic realignment, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.                            

 


            

Contact Data